EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study

Maria Agnese Fabbri iD, Alberto Fulvi, Matteo Vergati, Giuliana D'Auria, Patrizia Vici, Lorena Filomeno, Teresa Arcuri, Antonella Palazzo, Fabrizio Nelli, Cristina Fiore, Ilaria Portarena, Pina Tiziana Falbo und 13 weitere

The Breast Journal · 2025

DOI: 10.1155/tbj/8976679 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Breast Journal, 2025. Verfasst von Maria Agnese Fabbri und 24 weiteren Autor:innen. Beteiligte Einrichtung: UOC Oncologia, Ospedale Belcolle, Viterbo, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Medication Adherence. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In estrogen‐receptor positive breast cancer (BC), oral adjuvant endocrine therapy (ET) administered for at least 5 years significantly reduces risks of disease recurrence and mortality. Among available therapies, aromatase inhibitors (AI) showed high efficacy. However, adherence to ET is very poor. Effective support by physicians requires the identification of factors influencing AI treatment adherence. Materials and Methods A prospective/retrospective multicentric study was conducted in adult BC women currently undergoing adjuvant treatment with AI. Study endpoints were assessed through a questionnaire after at least 12 months of adjuvant therapy. The primary objective was the assessment of the adherence to AI; secondary objectives were the assessment of adverse events (AEs) of the therapy and the solutions adopted for AEs.

Results

Overall, 903 patients with a median age of 63 years were enrolled. Two hundred and forty‐three patients (26.9%) stated they do not respect the intake times. Adherence was not influenced by the number of drugs other than the ones for BC or by age. Most patients (87%) suffered from one or more AEs. The most frequent are musculoskeletal symptoms, which occurred in 86.2% of the patients. 74.5% and 74.4% of participants reported hot flashes and tiredness, respectively. No structured or uniform responses were reported regarding the strategy for solving side effects: answers were almost generic, but for more than 50% of patients, the final outcome was positive. AEs were a driver for nonadherence in only 19.6% of patients.

Conclusion

Survey results should be considered as an overview of AI therapy adherence in BC patients. We showed that the oncologist has a key role in improving therapeutic adherence and, as a consequence, in improving clinical outcome. Through a dialogue with the patient and a synergistic interaction with other clinical specialists, a greater awareness of the importance of the treatment could be warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsMedication AdherenceAdultAgedAged, 80 and overFemaleHumansMiddle AgedChemotherapy, AdjuvantItalyProspective StudiesRetrospective StudiesSurveys and Questionnaires

Stichwörter der Autor:innen

adherenceadjuvant hormonal therapyaromatase inhibitorsbreast cancerside effects

Substanzen

Antineoplastic Agents, HormonalAromatase Inhibitors

Autor:innen und Institutionen

  • UOC Oncologia, Ospedale Belcolle, Viterbo, Italy.
  • UOC Oncologia Medica 1, IRCCS Istituto Nazionale Tumori Regina Elena, Roma, Italy.
  • UOC Oncologia Interpresidio Pertini/S. Eugenio, Roma, Italy.
  • UOSD Sperimentazioni di Fase IV, IRCCS Istituto Nazionale Tumori Regina Elena, Roma, Italy.
  • UOC Oncologia medica, Fondazione Policlinico Gemelli IRCCS, Roma, Italy.
  • UOC Oncologia Medica, Policlinico Tor Vergata, Roma, Italy, ptvonline.it.

ORCID-Profile: Maria Agnese Fabbri, Simone Scagnoli

Zitieren

APA

Fabbri, M. A., Fulvi, A., Vergati, M., D'Auria, G., Vici, P., Filomeno, L., Arcuri, T., Palazzo, A., Nelli, F., Fiore, C., Portarena, I., Falbo, P. T., Rossi, R., Alesini, D., Sini, V., Pace, R., Frittelli, P., Corsi, D. C., Palombi, L., …, & La Cesa, A. (2025). Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study. The Breast Journal. https://doi.org/10.1155/tbj/8976679

Vancouver

Fabbri MA, Fulvi A, Vergati M, D'Auria G, Vici P, Filomeno L, et al. Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study. The Breast Journal. 2025. doi:10.1155/tbj/8976679

BibTeX
@article{Fabbri2025,
  author = {Fabbri, Maria Agnese and Fulvi, Alberto and Vergati, Matteo and D'Auria, Giuliana and Vici, Patrizia and Filomeno, Lorena and Arcuri, Teresa and Palazzo, Antonella and Nelli, Fabrizio and Fiore, Cristina and Portarena, Ilaria and Falbo, Pina Tiziana and Rossi, Rosalinda and Alesini, Daniele and Sini, Valentina and Pace, Roberta and Frittelli, Patrizia and Corsi, Domenico Cristiano and Palombi, Lucia and Pisegna, Simona and Botticelli, Andrea and Scagnoli, Simone and Pistillucci, Giorgio and Giordani, Erica and La Cesa, Annalisa},
  title = {Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study},
  journal = {The Breast Journal},
  year = {2025},
  doi = {10.1155/tbj/8976679}
}
Kostenlos starten →